

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: TIE2/21 - Allergy Control Scheme (Total IgE)

Deadline: 24.09.2021

|                                                      |                                                                      |                                          |
|------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------|
| RoM = robust average                                 | AV = assigned value                                                  | Dmax = acceptable percent difference     |
| SD = standard deviation                              | CRV = certified reference value                                      | LL = lower limit                         |
| CV = coefficient of variation                        | RV = reference value                                                 | UL = upper limit                         |
| Ntot = total number of the participants              | CVE = consensus value from experts                                   | Neva = number of evaluated participants  |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants                          | Nsuc = number of successful participants |
|                                                      | CVPG = consensus value from participants groups                      | Srel = success (relative)                |
|                                                      | U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2) |                                          |

| Test                              | [unit] | Comparability |      |        |                  |                   |      |                 |                  |     |     |                  |                  |                  |
|-----------------------------------|--------|---------------|------|--------|------------------|-------------------|------|-----------------|------------------|-----|-----|------------------|------------------|------------------|
|                                   |        | RoM           | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub>  | AV   | U <sub>AV</sub> | D <sub>max</sub> | LL  | UL  | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |
| <b>(280) Total IgE</b>            |        |               |      |        | 32               |                   |      |                 |                  |     | 32  | 30               | 94%              |                  |
| ----- Samples and groups -----    | [kU/L] |               |      |        |                  |                   |      |                 |                  |     |     |                  |                  |                  |
| <b>Sample A</b>                   |        | 7,46          | 6,8  | 91     | 32               | CVP               | 3,82 | 0,46            | asym.            | 1   | 30  | 32               | 31               | 97%              |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI) |        | 2,63          | 0,79 | 30     | 12               |                   |      |                 |                  |     |     | 12               |                  |                  |
| (6) IMT, IMN                      |        | 9,63          | 6,7  | 70     | 17               |                   |      |                 |                  |     |     | 17               |                  |                  |
| Other                             |        |               |      |        | 3                |                   |      |                 |                  |     |     | 3                |                  |                  |
| -----                             |        |               |      |        |                  | 1x 2, 1x 3, 1x 99 |      |                 |                  |     |     |                  |                  |                  |
| <b>Sample B</b>                   |        | 378           | 39   | 10     | 32               | CVP               | 385  | 7,4             | 25%              | 288 | 482 | 32               | 31               | 97%              |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI) |        | 388           | 36   | 9,3    | 12               |                   |      |                 |                  |     |     | 12               |                  |                  |
| (6) IMT, IMN                      |        | 375           | 37   | 9,9    | 17               |                   |      |                 |                  |     |     | 17               |                  |                  |
| Other                             |        |               |      |        | 3                |                   |      |                 |                  |     |     | 3                |                  |                  |
| -----                             |        |               |      |        |                  | 1x 2, 1x 3, 1x 99 |      |                 |                  |     |     |                  |                  |                  |

st\_kn\_p

End of report

Printed: 02.10.2021